Jani Sakari Saarela

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1104048/publications.pdf Version: 2024-02-01



IANI SAKADI SAADELA

#	Article	IF	CITATIONS
1	Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments. Briefings in Bioinformatics, 2022, 23, .	6.5	7
2	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discovery, 2022, 12, 388-401.	9.4	73
3	Genome-wide siRNA screening reveals several host receptors for the binding of human gut commensal Bifidobacterium bifidum. Npj Biofilms and Microbiomes, 2022, 8, .	6.4	1
4	<i>In Vitro</i> Identification and <i>In Vivo</i> Confirmation of Inhibitors for <i>Sweet Potato Chlorotic Stunt Virus</i> RNA Silencing Suppressor, a Viral RNase III. Journal of Virology, 2021, 95, .	3.4	3
5	High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome. Cancers, 2021, 13, 2907.	3.7	3
6	High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. Scientific Reports, 2021, 11, 14755.	3.3	7
7	High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro. Biomolecules, 2020, 10, 1365.	4.0	22
8	Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma. Science Translational Medicine, 2020, 12, .	12.4	22
9	Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics, 2020, 36, 3602-3604.	4.1	68
10	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. Clinical Cancer Research, 2020, 26, 4107-4119.	7.0	68
11	Development of FRETâ€based highâ€throughput screening for viral RNase III inhibitors. Molecular Plant Pathology, 2020, 21, 961-974.	4.2	3
12	Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer. Npj Systems Biology and Applications, 2019, 5, 20.	3.0	32
13	Prediction of drug combination effects with a minimal set of experiments. Nature Machine Intelligence, 2019, 1, 568-577.	16.0	99
14	Combined gene essentiality scoring improves the prediction of cancer dependency maps. EBioMedicine, 2019, 50, 67-80.	6.1	18
15	Methods for High-throughput Drug Combination Screening and Synergy Scoring. Methods in Molecular Biology, 2018, 1711, 351-398.	0.9	140
16	Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner. Clinical Cancer Research, 2017, 23, 6697-6707.	7.0	41
17	Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. Viruses, 2017, 9, 271.	3.3	39
18	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. Blood, 2017, 130, 854-854.	1.4	1

JANI SAKARI SAARELA

#	Article	IF	CITATIONS
19	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. Oncotarget, 2017, 8, 18381-18398.	1.8	14
20	BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine. Scientific Reports, 2016, 6, 28217.	3.3	23
21	High Throughput siRNA Screening Using Reverse Transfection. Methods in Molecular Biology, 2016, 1470, 25-37.	0.9	1
22	Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing. Journal of the Association for Laboratory Automation, 2016, 21, 27-36.	2.8	22
23	Discovery of MINC1, a GTPase-Activating Protein Small Molecule Inhibitor, Targeting MgcRacGAP. Combinatorial Chemistry and High Throughput Screening, 2015, 18, 3-17.	1.1	9
24	Relevance Rank Platform (RRP) for Functional Filtering of High Content Protein–Protein Interaction Data*. Molecular and Cellular Proteomics, 2015, 14, 3274-3283.	3.8	19
25	Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles. Chemistry and Biology, 2015, 22, 1144-1155.	6.0	22
26	The High Throughput Biomedicine Unit at the Institute for Molecular Medicine Finland: High Throughput Screening Meets Precision Medicine. Combinatorial Chemistry and High Throughput Screening, 2014, 17, 377-386.	1.1	9
27	Avian phospholipid transfer protein causes HDL conversion without affecting cholesterol efflux from macrophages. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 781-789.	2.4	6
28	The patatin-like lipase family in Gallus gallus. BMC Genomics, 2008, 9, 281.	2.8	30
29	Glycosylation, transport, and complex formation of palmitoyl protein thioesterase 1 (PPT1) – distinct characteristics in neurons. BMC Cell Biology, 2007, 8, 22.	3.0	42
30	Autoproteolytic activation of human aspartylglucosaminidase. Biochemical Journal, 2004, 378, 363-371.	3.7	25
31	APECED-causing mutations in AIRE reveal the functional domains of the protein. Human Mutation, 2004, 23, 245-257.	2.5	102
32	A novel aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase. Human Mutation, 2004, 24, 350-351.	2.5	26
33	Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations. Human Molecular Genetics, 2001, 10, 983-995.	2.9	57
34	Activation and Oligomerization of Aspartylglucosaminidase. Journal of Biological Chemistry, 1998, 273, 25320-25328.	3.4	40